Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multi-center Study of Ruxolitinib for the Treatment of Chinese Patients With Grade II-IV Corticosteroid-refractory Acute Graft Versus Host Disease

NCT06462469 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06462469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multi-center Study of Ruxolitinib for the Treatment of Chinese Patients With Grade II-IV Corticosteroid-refractory Acute Graft Versus Host Disease
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 4, 2024
Completion date
July 8, 2027
Enrollment
36 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

steroid-refractory acute graft versus host disease